FT : ‘Event-driven’ hedge funds leap into lead after rush to invest

‘Event-driven’ hedge funds leap into lead after rush to invest

When a hedge fund manager makes a paper profit of $1bn in a single day, it attracts attention. Bill Ackman’s 9.7 per cent stake in Allergan, the maker of Botox injections, rose by that much last month when he revealed he was working with Valeant Pharmaceuticals on a hostile bid for the company. It was a trade that attracted wide comment from lawyers and rivals for its unusual structure and its audacity, but for investors it was simply the fact of such a large profit that caught the eye.

It was another example that a creative hedge fund manager can make his own profits, no matter what is going on in the wider market, and the best justification yet for the headlong rush to put money into “event-driven” hedge fund strategies over the past year. The activists, such as Mr Ackman and peers including Dan Loeb and Barry Rosenstein, whose goal is to cajole companies into corporate activity, have generated most of the headlines, but the phenomenon has been seen across the whole category of event-driven funds. These include managers who make bets around mergers and acquisitions, for example, or even around regular events such as earnings or share buybacks. In all, event-driven funds attracted $29.6bn in new money last year, more than any other hedge fund category, and a further $4.1bn in the first quarter of 2014, according to data provider Hedge Fund Research. Assets under management are more than double what they were in 2008. These funds have outperformed the hedge fund industry as a whole in all but two quarters since the start of 2011 – making them even more popular – and even as the industry has suffered two rocky months, turning in negative returns overall, event-driven funds have stayed profitable. The question, as equity market valuations get more stretched and investors become more nervous about a correction, is whether the boom in event-driven funds will prove to be a bull market phenomenon, or whether these managers go on to prove they have found the holy grail of hedge fund investing, uncorrelated returns. SkyBridge Capital, a fund of funds, has 40 per cent of its portfolio allocated to event-driven strategies, and although it has dialled back investments with managers who are the most correlated with the stock market in recent months, founder Anthony Scaramucci says he still believes activists in particular have further to run.

“Every 30 years in the modern era, corporate America has had to go through a period of slimming down and restructuring,” says Mr Scaramucci. “In the 1980s, it was driven by the corporate raider, now it is the activist. Every 30 years, the companies get fat, they get clubby.” Some of the most conservative event-driven strategies of recent years have lost their allure as more and more funds have crowded in, according to Barry Gill, portfolio manager at UBS O’Connor. These plain vanilla strategies include short-term bets around specific triggers such as earnings, usually made up of betting in favour of one stock and short selling a rival. “The more capital, the lower the returns, since there are lots of people with similar ideas and ways of thinking about the world,” says Mr Gill, adding that the bias towards using mid and small-cap stocks has exacerbated losses in this subsector in recent weeks as small-caps have sharply underperformed. If these conservative strategies are played out, and activism is halfway through its cycle, Mr Gill says, the next bright spot within event-driven strategies is merger arbitrage. A boom in US merger and acquisition deals appears to be spreading to Europe, not least via Pfizer’s $100bn-plus bid for AstraZeneca, giving traders numerous options to bet on the outcome of the battle and on the likely shifts in the two companies’ shares and bonds. A recent rise in European deals has prompted hedge fund investors to seek funds with exposure to the region, and for hedge funds themselves to look to hire more managers who are able to trade such situations effectively. A recent report by Lyxor Alternatives, a France based fund of hedge funds, referred to an “M&A frenzy”, arguing that the European merger cycle would mean a large number of opportunities would open up for managers. Andrew Garthwaite, chief global equity strategist at Credit Suisse, argued at a recent conference in London organised by the bank on event-driven investing that M&A activity tended to lag the broader stock market by a year, meaning Europe was now primed for a fit of takeover activity. The bank’s hedge fund investor survey, which polled over 500 respondents representing $1.16tn in hedge fund assets, showed demand from investors for event-driven strategies almost doubled from the year before. Mr Scaramucci says: “I think we’re in the first or second inning in this trade, and I predict we’ll have more money to allocate to these strategies in the future.”

Pfizer Holders Could Face Tax Hit in a Deal for AstraZeneca


Pfizer Holders Could Face Tax Hit in a Deal for AstraZeneca

Pfizer Inc. could cut its tax bill by hundreds of millions of dollars if it buys rival AstraZeneca PLC, but thousands of Pfizer shareholders could face a tax hit if the deal goes through.
The hit would stem from a little-known provision of U.S. tax rules that is triggered when a U.S. company buys a firm overseas and relocates there to reduce its taxes. Under the rules, Pfizer shareholders with stock in taxable accounts would owe capital-gains tax on the appreciation in their shares when they are converted into stock in the combined company, said Robert Willens, an independent tax expert based in New York.
Shareholders who hold stock in tax-deferred accounts such as IRAs and 401(k) plans wouldn't owe tax as a result of a deal, he said.
Pfizer has proposed to buy AstraZeneca for $106 billion in cash and stock, but AstraZeneca, based in London, rejected the offer, saying it substantially undervalued the company. There is no certainty a deal will be reached. This week Pfizer said it is reviewing its options, which could include walking away.
A Pfizer spokeswoman said the company was aware of the potential for the tax, which is why it mentioned that it expected Pfizer shareholders would face a "taxable event" in an April 28 news release confirming discussions with AstraZeneca on a deal.
There are more than 6.38 billion common shares outstanding of Pfizer, according to the company's annual report, which was released in February. Some 27% of those shares appear to be held directly by individuals rather than institutions, according to FactSet, a financial data provider.
Longtime Pfizer shareholders have seen the stock rise considerably over the years. Since Ian Read took over as Pfizer chief executive in December 2010, the company's stock has climbed 74%. In midafternoon trading Thursday, it was at $29.12, Since late 1984, each Pfizer share has been split into 24 shares and has gained 1,647%, not including dividends.
A merger could leave some investors short of cash to pay their tax bill, since they would realize no cash when the shares are exchanged, as they would after selling shares.
Traci Medford-Rosow, former chief intellectual property counsel at Pfizer, who worked at the company for more than 30 years, said she holds more than 1,000 of its shares. She said she wasn't aware of a potential tax hit and would probably have to "scramble around to get the money" to pay the tax.
"That would be very difficult for people if they had a paper gain but no real gain, and they were hit for a tax they don't have in their pocket," said Ms. Medford-Rosow, 58 years old, now an intellectual property lawyer at law firm Richardson & Rosow in New York.
Among the hardest-hit could be investors who have owned Pfizer shares for many years, especially those who planned to continue holding until their death. Because of a provision known as the "step up in basis," estates of taxpayers who own assets at death don't owe capital-gains tax on their appreciated value.
For example, if an investor bought a share of stock at $5 that is now worth $100, a sale would trigger capital-gains taxes on $95. But if the investor died owning the share, no capital-gains tax would be due. Instead, it would become part of the person's estate at full market value.

WSJ Snapchat Settles FTC Charges


Snapchat Settles FTC Charges
Mobile Messaging App Developer Will Face Privacy Monitoring for 20 Years


The FTC said Snapchat also is settling commission charges that it misrepresented its data collection practices. Photo: Agence France-Presse/Getty Images
By BRENT KENDALL and ELIZABETH DWOSKIN
Mobile messaging app developer Snapchat has agreed to settle Federal Trade Commission charges that it deceived consumers about the disappearing nature of the messages sent through its service.
The FTC said Snapchat also is settling commission charges that it misrepresented its data collection practices and didn't employ reasonable security measures to protect users' personal information.
Snapchat agreed to a settlement that prohibits it from making future misrepresentations about the privacy, security or confidentiality of users' information, the FTC said Thursday. The commission said the company also will be required to implement a privacy program that will be subject to monitoring for 20 years.
Among the allegations in the FTC's complaint, the commission said Snapchat misrepresented that photo and video messages sent over its service disappear forever once a time-limited period has expired.
Despite those claims, there are several ways in which a message recipient can use tools outside of the Snapchat app to view messages indefinitely, the FTC said.
In a company blog post announcing the settlement, Snapchat said the company had been focused on growth, and learned by making mistakes. "While we were focused on building, some things didn't get the attention they could have," the post said. "One of those was being more precise with how we communicated with the Snapchat community."
The post said that the company had made changes over the last year. "Even before today's consent decree was announced, we had resolved most of those concerns over the past year by improving the wording of our privacy policy, app description, and in-app just-in-time notifications. And we continue to invest heavily in security and countermeasures to prevent abuse."

WSJ : ECB's Draghi Talks Up a Summer Storm

ECB's Draghi Talks Up a Summer Storm

Mario Draghi's strategy of talking dovishly while keeping monetary policy unchanged has run out of road.

The president of the European Central Bank on Thursday heavily hinted at action in June, saying the governing council was "comfortable" with that idea, subject to new information that will be available by then. But what exact course of action the ECB might take then isn't clear.

Mr. Draghi certainly caught the market off guard. He kicked off Thursday's news conference with remarks that were almost identical to those he made a month ago. That helped push the euro up to within a whisker of $1.40. But then he dropped several bombshells, saying the exchange rate was cause for "serious concern" in the context of low inflation; that the ECB wasn't resigned to tolerating low inflation; and that policy makers were "comfortable with acting next time" subject to new staff forecasts on growth and inflation. The euro promptly tumbled over a cent against the dollar, and stocks and euro-zone bonds rallied.

Mr. Draghi's reversal raises many questions. First, if there is a consensus to act, why wait? Second, how much has the ECB's thinking changed since March? Back then, a forecast for inflation of just 1% this year and 1.7% by late 2016 was judged as allowing monetary policy to remain on hold. True, the June forecasts are likely to show lower inflation for this year—so far it has averaged 0.7%—but may also show higher economic growth. And it is medium-term inflation that policy will be able to influence, not the data unfolding in the coming months.

Most important of all, what might the ECB do in June if it does decide to act? The focus on the strength of the currency suggests that a cut in interest rates combined with a negative rate on the cash that banks deposit at the ECB might be in the cards. ECB officials have previously suggested that this would be the first course of action.

But the ECB's newfound unwillingness to tolerate low inflation points to a potentially bigger response: Mr. Draghi on April 24 said that a worsening of the medium-term outlook on this front could lead to asset purchases, or quantitative easing. However, he said the context for doing so might be a broad-based weakening of demand or a big positive supply shock—neither of which seem to have materialized. QE remains a drastic policy step, and it isn't clear the ECB has worked out what to buy, or how.

Markets will comb speeches from ECB officials in coming days for further guidance. Previously, less obvious hints at ECB action have been followed swiftly by talk about the practical difficulties involved. Mr. Draghi's comments Thursday, however, will make it very difficult to row back now.

(BFW) EU Would Veto U.K. Govt Intervention in AstraZeneca Bi



EU Would Veto U.K. Govt Intervention in AstraZeneca Bid: Reuters
2014-05-08 15:33:03.212 GMT


By James Ludden
     May 8 (Bloomberg) -- European Commission allows
intervention by EU national governments only in exceptional
cases, Reuters reports, citing competition lawyers.
  * Commission would probably rule on transaction
  * U.K. govt would have to create new category if it were to
    invoke public interest test in any AstraZeneca takeover;
    Commission unlikely to back such a move: Reuters




For Related News and Information:
First Word scrolling panel: FIRST<GO>
First Word newswire: NH BFW<GO>

To contact the reporter on this story:
James Ludden in London at +44-20-7673-2645 or
jludden@bloomberg.net
To contact the editors responsible for this story:
Andrew Rummer at +44-20-7073-3722 or
arummer@bloomberg.net
James Ludden

(BFW) Liberty Global Remains Confident Ziggo Deal to Close i



Liberty Global Remains Confident Ziggo Deal to Close in 2H 2014
2014-05-08 15:59:20.746 GMT


By Elco van Groningen
     May 8 (Bloomberg) -- Liberty has been and will be in
constructive dialogue with European Commission, spokesman Bert
Holtkamp says by e-mail.
  * Says co. is confident it can address any competition issues
  * Liberty will keep working with commission in coming months,
    Holtkamp says
  * NOTE: Earlier, Liberty Global Gets Extended EU Antitrust
    Probe of Ziggo Deal


For Related News and Information:
First Word scrolling panel: FIRST<GO>
First Word newswire: NH BFW<GO>

To contact the reporter on this story:
Elco van Groningen in Amsterdam at +31-20-589-8517 or
vangroningen@bloomberg.net
To contact the editor responsible for this story:
Simon Thiel at +44-20-7673-2814 or
sthiel1@bloomberg.net

(BFW) Prisa Says Class B Shares to Be Converted to Class A i



Prisa Says Class B Shares to Be Converted to Class A in June
2014-05-08 16:06:19.590 GMT


By Charles Penty
     May 8 (Bloomberg) -- Prisa comments in regulatory filing
today.
  * NOTE: For link to filing, click on:
    {http://tinyurl.com/mz4o88e}

Link to Company News:{PRS SM <Equity> CN <GO>}

For Related News and Information:
First Word scrolling panel: {FIRST<GO>}
First Word newswire: {NH BFW<GO>}

To contact the editor responsible for this story:
Charles Penty at +34-91-700-9654 or
cpenty@bloomberg.net

>>>Apple + Samsung = 106% of handset operating profits in Q1

Apple + Samsung = 106% of handset operating profits in Q1

Canccord Genuity's U.S. surveys indicated the Galaxy S5 was the #1 selling smartphone at all four tier-1 U.S. carriers in April (iPhone 5S was #2). They believe Apple and Samsung (SSNLF) once again dominated handset industry operating profits and combined to capture a remarkable 106% of Q1/14 handset industry profits as other leading OEMs such as BlackBerry, Nokia (MSFT), and HTC posted operating losses or near breakeven results. Thet believe their RFIC coverage cos AVGO, SWKS, RFMD, and TQNT and baseband supplier QCOM are well positioned to benefit from the China TD-LTE smartphone ramp for the remainder of 2014. They anticipate re-accelerating smartphone-derived royalties for ARMH in H2/14.

>>> (Makor) MRPT - Top Trading Ideas - LONG ENI / SHORT TOTAL, IXC


Trade action flash – Long ENI / Short Total, ishares global energy (IXC)

May 08, 2014

MRPT© mean reverting pair trading strategies      TOP TRADING IDEAS

ENI IM: Eur 18.88; FP FP: Eur 52.05; IXC US: US$ 47.12

We recommend going long ENI while shorting Total and the iSHARES global energy ETF (IXC US).  The stock has been underperforming the sector since early 2013 and has become as a result one of the most attractive global oil companies from a relative value basis.  ENI is particularly mean reverting with Total and the iSHARES global energy ETF.  We could target easily a 5-10% relative performance come-back for ENI.  The trade is added to our Top Trading Ideas portfolio.

Full report attached

 

Makor Capital

11 Menachem Begin St., 26th FL

Ramat Gan 52681

Israel

 

Tel          +972 3 5453 768

Fax         +972 3 7162 680

 

Research Disclaimer

This publication has been prepared by Makor Capital Limited (“Makor Capital”) and is intended for professional or qualified investors only. Makor Securities LLP (“Makor Securities”)is distributing this material to its clients who are Eligible Counterparties or Professional Clients under FSA Rules. It may also be disseminated to persons who are Investment Professionals within the meaning of the Financial Services and Markets Act 2000 (Financial Promotion) order 2005.  In the United States Makor Capital only distributes this material to major US institutional investors (as that term is defined in Rule 15 a-6 of the Securities and Exchange Act of 1934) and to SEC registered broker-dealers or  banks acting in a broker –dealer capacity” If you do not fall into any of these categories you should disregard it.

 

This research material is a marketing communication.  It is not investment research and has not been prepared in accordance with legal requirements designed to promote the independence of investment research. It is not subject to any prohibition on dealing ahead of the dissemination of investment research.   It has not been produced by Makor Securities. 

 

This material does not take into account the particular investment objectives, financial situation or needs of individual clients or other recipients. Before acting on this material, clients and other recipients should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice.

This material should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action.

This material is produced by research providers which Makor Securities believes to be reliable, but Makor Securities does not warrant or represent (expressly or impliedly) that it is accurate, complete, not misleading or as to its fitness for the purpose intended and it should not be relied upon as such.

Opinions expressed will be the current opinions of those producing the research as of the date appearing on this material only. We expect those producing the material in  this report to update it on a timely basis but can give no undertaking that they will do so and regulatory compliance or other reasons may prevent  them from doing so (or us from disseminating updated material). 

 

Members and employees of Makor Securities LLP, employees of Makor Capital, Makor Capital Markets and any firm producing this material (including Alternative Investment Management Research SA (“AIM&R”),) may from time to time have long or short positions in securities, warrants, futures, options, derivatives or other financial instruments referred to in this material. For Makor Securities, this information is set out in our Conflicts of Interest Policy which is available on request.  Policies for the production of research from research providers (including AIM&R) are available on request.

Unless otherwise stated, share prices provided within this material are as at the close of business on the day prior to the date of the material.

Neither the whole nor any part of this material may be duplicated in any form or by any means. Neither should any of this material be redistributed or disclosed to anyone without prior consent. This material is issued for general information and discussion purposes only. None of  Makor Securities, Makor Capital, Makor Capital Markets nor AIM&R accepts  liability whatsoever for any direct, indirect or consequential loss or damage of any kind arising out of the use of all or any of this material.

 

The services, securities and investments discussed in this material may not be available to, nor are suitable for all investors. Investors should make their own investment decisions based upon their own financial objectives and financial resources and it should be noted that investment involves risk, including the risk of capital loss. Past performance is no guide to future performance. In relation to securities denominated in foreign currency, movements in exchange rates will have an effect on the value, either favourable or unfavourable.

 

Entities

 

Makor Securities LLP is authorised and regulated by the Financial Services Authority (FSA registration number 556034) of Dover House, 34 Dover Street, London W1S 4NG.

Makor Capital, company number 514456466, is incorporated in Israel and is a 100% held subsidiary of Makor Holdings Pte Ltd incorporated in Singapore.

Makor Capital Markets SA, company number CH-660.2.999.011-0 is incorporated in Switzerland and is also a 100% held subsidiary of Makor Holdings Pte Ltd.

AIM&R is incorporated in Switzerland; company number CH-660.1.533.997-8

 

 

>>> Fed's Tarullo (dovish, FOMC voter): Should replace risk-weighted capital with measures based on stress tests

Fed's Tarullo (dovish, FOMC voter): Should replace risk-weighted capital with measures based on stress tests; one size fits all approach to bank regulation has been abandoned - comments from Bank Regulation Conference in Chicago - Threshold for enhanced bank supervision could be raised to $100 billion from $50 billion. - Financial regulation needs to be broadened to cover non-bank financial firms. - Need to re-examine exclusion of small community banks from certain financial activities. - Need to establish minimum margin requirements for securities financing.